Get the Stockscreener App
38.50
7.15%
2.57
After Hours:
39.00
0.50
+1.30%
Mineralys Therapeutics Inc stock is traded at $38.50, with a volume of 1.98M.
It is up +7.15% in the last 24 hours and up +196.15% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$35.93
Open:
$36.68
24h Volume:
1.98M
Relative Volume:
1.53
Market Cap:
$2.55B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-14.10
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+33.40%
1M Performance:
+196.15%
6M Performance:
+265.97%
1Y Performance:
+225.17%
1-Day Range:
$35.93
$38.54
1-Week Range:
$27.08
$38.54
52-Week Range:
$8.241
$38.54
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
38.50 | 2.79B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Why Mineralys Therapeutics Stock is Climbing - TipRanks
Mineralys Therapeutics stock hits all-time high at 37.42 USD By Investing.com - Investing.com Canada
Mineralys Therapeutics stock hits all-time high at 37.42 USD - Investing.com
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Tuesday 9/9 Insider Buying Report: MLYS, KMTS - Nasdaq
Mineralys Therapeutics Stock (MLYS) Opinions on $175M Public Offering and Clinical Trial Results - Quiver Quantitative
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
Major Investment Alert: Mineralys Therapeutics Sees Huge Stock Purchase! - TipRanks
Ra Capital Healthcare Fund buys Mineralys Therapeutics shares for $30m - Investing.com India
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position - TipRanks
H.C. Wainwright reiterates Buy rating on Mineralys stock, citing lorundrostat potential - Investing.com Nigeria
Mineralys Therapeutics Shares Surge on Promising Trial Results - TipRanks
Drawdown in Mineralys Therapeutics Inc. May Be Nearing EndQuarterly Profit Summary & Breakout Confirmation Trade Signals - beatles.ru
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - Mitrade
Should value investors consider Mineralys Therapeutics Inc.July 2025 Trade Ideas & Real-Time Price Movement Reports - beatles.ru
Will Mineralys Therapeutics Inc. benefit from current market trendsMarket Performance Summary & Precise Buy Zone Identification - 뉴스영
Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position - TipRanks
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
How moving averages guide Mineralys Therapeutics Inc. trading2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Is Mineralys Therapeutics Inc. affected by consumer sentiment2025 Volume Leaders & Reliable Volume Spike Trade Alerts - خودرو بانک
Is Mineralys Therapeutics Inc. undervalued by DCF analysisWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک
Mineralys reports positive subgroup data for hypertension drug By Investing.com - Investing.com Canada
Can Mineralys Therapeutics Inc. disrupt its industryJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Is Mineralys Therapeutics Inc. a strong candidate for buy and hold2025 Growth vs Value & Weekly Top Gainers Alerts - خودرو بانک
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
Candlestick signals on Mineralys Therapeutics Inc. stock todayInsider Selling & Weekly Top Gainers Trade List - Newser
How to track smart money flows in Mineralys Therapeutics Inc.Weekly Trend Report & Fast Moving Market Watchlists - Newser
Institutional scanner results for Mineralys Therapeutics Inc.July 2025 EndofMonth & Daily Profit Focused Screening - Newser
Will Mineralys Therapeutics Inc. announce a stock split2025 Geopolitical Influence & AI Based Trade Execution Alerts - خودرو بانک
Mineralys Therapeutics Shares Surge on Promising Drug Trials - TipRanks
How sentiment analysis helps forecast Mineralys Therapeutics Inc.Trade Ideas & Weekly Top Gainers Trade List - Newser
Does Mineralys Therapeutics Inc. stock benefit from AI growthJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Using RSI to spot recovery in Mineralys Therapeutics Inc.2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Mineralys Therapeutics closes $287.5 million public offering By Investing.com - Investing.com Australia
Mineralys Therapeutics presents subgroup analyses of phase 3 launch-htn trial demonstrating efficacy and safety of lorundrostat in hypertension participants with high unmet medical need - MarketScreener
Short interest data insights for Mineralys Therapeutics Inc.Trade Volume Summary & Accurate Trade Setup Notifications - Newser
Rapafusyn Pharmaceuticals’ $44M raise; CAGE Bio’s atopic dermatitis data - Endpoints News
Mineralys Says Lorundrostat Shows 'Meaningful' Blood Pressure Reductions in Phase 3 Trial - MarketScreener
Mineralys reports positive subgroup data for hypertension drug - Investing.com
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need - The Manila Times
16.9mmHg Blood Pressure Reduction: Mineralys' New Drug Shows Promise for Hard-to-Treat Hypertension Patients - Stock Titan
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Insider Buying & Free Verified High Yield Trade Plans - Newser
Is Mineralys Therapeutics Inc. reversing from oversold territoryJuly 2025 Institutional & Verified Swing Trading Watchlist - Newser
How to interpret RSI for Mineralys Therapeutics Inc. stock2025 Technical Patterns & Risk Managed Investment Signals - Newser
Is Mineralys Therapeutics Inc.’s ROIC above industry average2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):